Compare Krispy Kreme Inc (DNUT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Pfizer Inc — how do they compare? Krispy Kreme Inc trades at $2.98 (market cap $521.37M), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 304.1× Krispy Kreme Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Pfizer Inc for 158 Days on average.
| DNUT | PFE | |
|---|---|---|
Market Cap | $521.37M | $158.56B |
Volume | 2,293,015 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $29.02 |
52-Week Low | $2.87 | $23.67 |
Typical Hold Time | 45 Days | 158 Days |
Enterprise Value | $1.76B | $210.06B |
Dividend Yield | 3.47% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% today, amid bearish technical signals and negative profitability. The company reported a significant net loss of $515.77M in 2025 despite $1.52B revenue, with negative margins and declining cash flow from operations. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, creating investor uncertainty alongside seasonal product launches.
The outlook remains challenged by persistent losses and high debt levels, though analyst consensus leans bullish with 50% buy ratings. Key risks include legal overhangs, competitive pressure, and execution on profitability. Valuation metrics show mixed signals with low P/S but negative earnings, requiring careful monitoring of turnaround efforts and legal developments.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
